论文部分内容阅读
目的探讨抗胆碱能药物索利那新和托特罗定在治疗膀胱过度活动症(OAB)中的应用,比较其临床疗效。方法分析2010年3月至2015年4月天津市西青医院收治的68例膀胱过度活动症患者的临床资料,将其分为治疗组(36例)和对照组(32例),治疗组采用新型抗胆碱药物索利那新治疗,5 mg,1次/d,晚饭后口服;对照组采用托特罗定治疗,2 mg,2次/d,早晚饭后口服;比较两组患者治疗前后临床症状及不良反应发生情况。结果患者在给予索利那新治疗后,最大尿流率、残余尿量、日间排尿次数、急迫性尿失禁次数、夜尿次数较托特罗定明显改善,差异有统计学意义(P<0.05);治疗组膀胱过度活动症评分生活质量评分明显优于对照组。结论抗胆碱能药物索利那新在治疗膀胱过度活动症中的效果优于托特罗定,能够更好地改善OAB患者的临床症状,减少药物不良反应的发生。
Objective To investigate the anticholinergic drugs solifenacin and tolterodine in the treatment of overactive bladder (OAB) in the application of its clinical efficacy. Methods The clinical data of 68 patients with overactive bladder who were treated in Xiqing Hospital of Tianjin from March 2010 to April 2015 were divided into treatment group (36 cases) and control group (32 cases). The treatment group The new anticholinergic drug solifenac treatment, 5 mg, 1 / d, after dinner orally; control group with tolterodine treatment, 2 mg, 2 times / d, after breakfast and dinner, oral; compare the two groups of patients before and after treatment Symptoms and adverse reactions occurred. Results After treatment with solifenacin, the maximum urinary flow rate, residual urine volume, number of urination during the day, number of urinary incontinence and nocturnal urination were significantly improved compared with that of tolterodine (P < 0.05). The quality of life score of overactive bladder in treatment group was significantly better than that in control group. Conclusion The anticholinergic drug solifenacin is superior to tolterodine in the treatment of overactive bladder and can improve the clinical symptoms and reduce the incidence of adverse drug reactions in OAB patients.